A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI

Trial Profile

A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 01 Mar 2018

At a glance

  • Drugs Erlotinib (Primary) ; Pacritinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Feb 2018 Status changed from recruiting to discontinued.
    • 10 May 2016 According to CTI BioPharma media release, FDA has removed the clinical hold.
    • 10 May 2016 Status changed from suspended to recruiting, as per CTI BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top